{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:23:51Z","timestamp":1790371431892,"version":"4.1.0"},"reference-count":39,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>By 2050, antimicrobial resistance (AMR) could lead to over 10\u2009million deaths annually and $100\u2009trillion in healthcare costs, making it one of the most urgent public health threats. The WHO recommends AMR National Action Plans (AMR NAPs) to address this threat, but the effectiveness of these plans is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We estimate the impact of AMR NAPs on retail sales of all antibiotics across 68 countries from 2014 to 2023 using IQVIAs Multinational Integrated Data Analysis System dataset. We further examine the effect of AMR NAP adoption on the proportion of antibiotic sales by WHO AWaRe (Access, Watch, Reserve) classification. To account for differences in the quality of the AMR NAP, we also examine if countries with a better NAP have differential use of antibiotics following its adoption. Finally, we explore whether countries with higher quality NAPs make differential use of azithromycin during the COVID-19 pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The adoption of an AMR NAP did not have a significant impact on total retail antibiotic sales. But when accounting for the quality of the AMR NAP, as identified from an evaluation of NAP plans, we find that high-scoring AMR NAPs significantly increased the proportion of retail sales from Access-class agents (0.031; 95%\u2009CI 0.003 to 0.06), and significantly decreased the proportion of Watch-class antibiotics (\u22120.03; 95%\u2009CI \u22120.055 to \u22120.005) as compared with those with lower scoring or no NAPs. Countries with high-scoring NAPs also exhibited lower retail azithromycin sales per 1000 persons during the COVID-19 pandemic (\u221249.08; 95%\u2009CI \u221289 to \u22129.16).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Countries with higher quality AMR NAPs exhibit more appropriate use of essential antibiotics overall and less inappropriate utilisation of azithromycin during the COVID-19 pandemic compared with those with no or low-scoring plans. Well-developed AMR NAPs may be a useful policy tool to promote more judicious antibiotic use globally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2025-020536","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:10:10Z","timestamp":1761646210000},"page":"e020536","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["An assessment of antimicrobial resistance national action plans and their impact on antibiotic use"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8071-7997","authenticated-orcid":false,"given":"Emily","family":"O\u2019Neill","sequence":"first","affiliation":[{"name":"LSE Health, The London School of Economics and Political Science, London, UK"},{"name":"Department of Health Services, Policy and Practice, Center for Health System Sustainability, Brown University School of Public Health, Providence, Rhode Island, USA"},{"name":"Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4514-9967","authenticated-orcid":false,"given":"Jinru","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy and Practice, Center for Health System Sustainability, Brown University School of Public Health, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Machado","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy and Practice, Center for Health System Sustainability, Brown University School of Public Health, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Galarraga","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy and Practice, The Center for Global Public Health, Brown University School of Public Health, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Papanicolas","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy and Practice, Center for Health System Sustainability, Brown University School of Public Health, Providence, Rhode Island, USA"},{"name":"Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island, USA"},{"name":"Department of Health Policy, London School of Economics, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"2025120102351912000_10.10.e020536.1","unstructured":"O\u2019Neill J . Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. Available: https:\/\/amr-review.org\/sites\/default\/files\/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf"},{"key":"2025120102351912000_10.10.e020536.2","unstructured":"O\u2019Neill J . TACKLING drug-resistant infections globally: final report and recommendations. 2016. Available: https:\/\/amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf"},{"key":"2025120102351912000_10.10.e020536.3","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics8030086","article-title":"Socioeconomic Enablers for Contagion: Factors Impelling the Antimicrobial Resistance Epidemic","volume":"8","author":"Collignon","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"2025120102351912000_10.10.e020536.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101848","article-title":"Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020-2022","volume":"57","author":"Nandi","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025120102351912000_10.10.e020536.5","unstructured":"Centers for Disease Control and Prevention . COVID-19 & antimicrobial resistance. Antimicrobial Resistance; 2024. Available: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/COVID-19.html [Accessed 11 Dec 2024]."},{"key":"2025120102351912000_10.10.e020536.6","unstructured":"WHO reports widespread overuse of antibiotics in patients hospitalized with covid-19. Available: https:\/\/www.who.int\/news\/item\/26-04-2024-who-reports-widespread-overuse-of-antibiotics-in-patients--hospitalized-with-covid-19 [Accessed 11 Dec 2024]."},{"key":"2025120102351912000_10.10.e020536.7","unstructured":"Antimicrobial resistance. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance [Accessed 11 Dec 2024]."},{"key":"2025120102351912000_10.10.e020536.8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1473-3099(22)00796-4","article-title":"Measuring the global response to antimicrobial resistance, 2020-21: a systematic governance analysis of 114 countries","volume":"23","author":"Patel","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025120102351912000_10.10.e020536.9","unstructured":"The who aware (access, watch, reserve) antibiotic book - infographics. Available: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2022.02 [Accessed 11 Dec 2024]."},{"key":"2025120102351912000_10.10.e020536.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30332-7"},{"key":"2025120102351912000_10.10.e020536.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30681-8"},{"key":"2025120102351912000_10.10.e020536.12","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S1470-2045(21)00706-3","article-title":"Essential medicines list in national cancer control plans: a secondary analysis from a global study","volume":"23","author":"Razis","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025120102351912000_10.10.e020536.13","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S1470-2045(22)00057-2","article-title":"Equity in national cancer control plans in the region of the Americas","volume":"23","author":"Loggetto","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025120102351912000_10.10.e020536.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263437","article-title":"Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020","volume":"17","author":"Bogdani\u0107","year":"2022","journal-title":"PLoS ONE"},{"key":"2025120102351912000_10.10.e020536.15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/IDR.S351827","article-title":"Azithromycin Misuse During the COVID-19 Pandemic: A Cross-Sectional Study from Jordan","volume":"15","author":"Abdelmalek","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2025120102351912000_10.10.e020536.16","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11081063","article-title":"Azithromycin through the Lens of the COVID-19 Treatment","volume":"11","author":"Kournoutou","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025120102351912000_10.10.e020536.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.11517"},{"key":"2025120102351912000_10.10.e020536.18","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12279"},{"key":"2025120102351912000_10.10.e020536.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30259-6"},{"key":"2025120102351912000_10.10.e020536.20","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2010.0317"},{"key":"2025120102351912000_10.10.e020536.21","unstructured":"WHO model list of essential medicines - 23rd list. 2023. Available: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02 [Accessed 11 Dec 2024]."},{"key":"2025120102351912000_10.10.e020536.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30415-3"},{"key":"2025120102351912000_10.10.e020536.23","unstructured":"Tripartite amr country self-assessment survey (tracss) 2019-2020. Available: https:\/\/www.who.int\/publications\/m\/item\/tripartite-amr-country-self-assessment-survey-(tracss)-2019-2020 [Accessed 11 Dec 2024]."},{"key":"2025120102351912000_10.10.e020536.24","unstructured":"Indicator metadata registry details. Available: https:\/\/www.who.int\/data\/gho\/indicator-metadata-registry\/imr-details\/116 [Accessed 11 Dec 2024]."},{"key":"2025120102351912000_10.10.e020536.25","unstructured":"Fantom NJ , Prince WC . World development indicators. 2014. Available: https:\/\/documents.worldbank.org\/en\/publication\/documents-reports\/documentdetail\/752121468182353172\/World-development-indicators-2014 [Accessed 11 Dec 2024]."},{"key":"2025120102351912000_10.10.e020536.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jeconom.2020.12.001"},{"key":"2025120102351912000_10.10.e020536.27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr541"},{"key":"2025120102351912000_10.10.e020536.28","doi-asserted-by":"publisher","DOI":"10.3201\/eid0812.010533"},{"key":"2025120102351912000_10.10.e020536.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2016.11.011"},{"key":"2025120102351912000_10.10.e020536.30","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1089\/mdr.2019.0497","article-title":"Cultural Drivers of Antibiotic Consumption in High-Income Countries: A Global Ecological Analysis","volume":"26","author":"Kenyon","year":"2020","journal-title":"Microb Drug Resist"},{"key":"2025120102351912000_10.10.e020536.31","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/cid\/ciab842","article-title":"Antibiotic Overuse and Stewardship at Hospital Discharge: The Reducing Overuse of Antibiotics at Discharge Home Framework","volume":"74","author":"Vaughn","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025120102351912000_10.10.e020536.32","doi-asserted-by":"publisher","DOI":"10.4161\/viru.21626"},{"key":"2025120102351912000_10.10.e020536.33","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.00140","article-title":"Antimicrobial Stewardship Programs in Resource Constrained Environments: Understanding and Addressing the Need of the Systems","volume":"8","author":"Kakkar","year":"2020","journal-title":"Front Public Health"},{"key":"2025120102351912000_10.10.e020536.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.07.010"},{"key":"2025120102351912000_10.10.e020536.35","unstructured":"Target . Global Database for Tracking Antimicrobial Resistance (AMR) Country Self- Assessment Survey (TrACSS), Available: http:\/\/amrcountryprogress.org\/ [Accessed 11 Dec 2024]."},{"key":"2025120102351912000_10.10.e020536.36","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1016\/S2214-109X(23)00019-0","article-title":"An analysis of existing national action plans for antimicrobial resistance-gaps and opportunities in strategies optimising antibiotic use in human populations","volume":"11","author":"Charani","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2025120102351912000_10.10.e020536.37","doi-asserted-by":"crossref","unstructured":"Zay Ya K , Patel J , Fink G . Assessing the associations between antimicrobial resistance policies and antibiotic use in low and middle income countries: a global analysis. SSRN [Preprint] 2023. doi:10.2139\/ssrn.4506558","DOI":"10.2139\/ssrn.4506558"},{"key":"2025120102351912000_10.10.e020536.38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajic.2021.11.016","article-title":"Reducing overuse of antibiotics at discharge home: A single-center mixed methods pilot study","volume":"50","author":"Giesler","year":"2022","journal-title":"Am J Infect Control"},{"key":"2025120102351912000_10.10.e020536.39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13756-019-0471-0","article-title":"Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review","volume":"8","author":"Nathwani","year":"2019","journal-title":"Antimicrob Resist Infect Control"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2025-020536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:35:44Z","timestamp":1764585344000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2025-020536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjgh-2025-020536"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2025-020536","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}